BALVERSA™ (erdafitinib)
AXERT® (almotriptan malate) Tablets
BALVERSA™ (erdafitinib)
CONCERTA® (methylphenidate HCI) Extended-release Tablets CII
DARZALEX® (daratumumab)
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
ERLEADA™ (apalutamide)
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension 39mg, 78mg, 117mg, 156mg, or 234mg
INVEGA SUSTENNA®
INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension 273mg, 410mg, 546mg, or 819mg
INVEGA TRINZA®
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKAMET® XR (canagliflozin/metformin HCl extended-release) tablets
INVOKAMET® XR
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
ORTHO TRI-CYCLEN® Lo (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® Lo
PREZCOBIX® (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) tablets
PROCRIT® (epoetin alfa)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA®
SPORANOX® (itraconazole)
SPRAVATO™ (esketamine) Nasal Spray CIII
STELARA® (ustekinumab)
SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
TOPAMAX® (topiramate) Tablets
TREMFYA® (guselkumab)
XARELTO® (rivaroxaban)
YONDELIS® (trabectedin)
ZYTIGA® (abiraterone acetate)

Need help paying for your BALVERSA™ (erdafitinib) prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for BALVERSA™. We have also listed most of the eligibility requirements for each, so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their websites to learn more.

To view programs that are best suited for you, select your coverage status for BALVERSA™ or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for BALVERSA™ or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are affiliated with Janssen.

They are updated on a regular basis. Be sure to visit the program site for additional information.

Janssen CarePath Savings Program for BALVERSA™

If you are eligible, the Janssen CarePath Savings Program may provide instant savings on your private or commercial health insurance out-of-pocket costs for BALVERSA™. Depending on your health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. Eligible patients pay $5 per fill, with a $25,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. See full eligibility requirements.

Sign up at MyJanssenCarePath.com/Express

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription co-insurance and co-payments
  • Have no gap in coverage

Medicaid

Medicaid and the Children's Health Insurance Program (CHIP) provide free or low-cost health coverage to millions of Americans, including some low-income people, families and children, pregnant women, the elderly, and people with disabilities.

Some states have expanded their Medicaid programs to cover all people below certain income levels.

No health insurance?

Check the Health Insurance Marketplace at www.HealthCare.gov to see if you can enroll in a plan.

Independent co-pay assistance foundations

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse any particular foundation. The foundations on this list are not the only ones that might be able to help you.

Patient Advocate Foundation

Other Resources

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if you might qualify for assistance, please contact a JJPAF program specialist at 800-652-6227 (Monday – Friday, 9:00 AM to 6:00 PM ET) or visit the foundation website at JJPAF.org.

April 15, 2019
Expand
Expand

IMPORTANT SAFETY INFORMATION

WHAT IS BALVERSA™ (erdafitinib)?

BALVERSA™ is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:

  • which has a certain type of abnormal "FGFR" gene, and
  • who have tried at least one other chemotherapy medicine that contains platinum, and it did not work or is no longer working.

Your healthcare provider will test your cancer for certain types of abnormal FGFR genes and make sure that BALVERSA™ is right for you.

It is not known if BALVERSA™ is safe and effective in children.

Before taking BALVERSA™, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BALVERSA™?

BALVERSA™ may cause serious side effects, including:

The most common side effects of BALVERSA™ include:

Tell your healthcare provider right away if you develop any nail or skin problems including nails separating from the nail bed, nail pain, nail bleeding, breaking of the nails, color or texture changes in your nails, infected skin around the nail, an itchy skin rash, dry skin, or cracks in the skin.

BALVERSA™ may affect fertility in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all possible side effects of BALVERSA™. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Keep BALVERSA™ out of the reach of children.

 

General information about the safe and effective use of BALVERSA™.
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use BALVERSA™ for a condition for which it was not prescribed. Do not give BALVERSA™ to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information about BALVERSA™ that is written for healthcare professionals.

 

Please click here to see full BALVERSA™ Prescribing Information.

cp-69606v1

IMPORTANT SAFETY INFORMATION

WHAT IS BALVERSA™ (erdafitinib)?

BALVERSA™ is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:

  • which has a certain type of abnormal "FGFR" gene, and
  • who have tried at least one other chemotherapy medicine that contains platinum, and it did not work or is no longer working.

Your healthcare provider will test your cancer for certain types of abnormal FGFR genes and make sure that BALVERSA™ is right for you.

It is not known if BALVERSA™ is safe and effective in children.

Before taking BALVERSA™, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BALVERSA™?

BALVERSA™ may cause serious side effects, including:

The most common side effects of BALVERSA™ include:

Tell your healthcare provider right away if you develop any nail or skin problems including nails separating from the nail bed, nail pain, nail bleeding, breaking of the nails, color or texture changes in your nails, infected skin around the nail, an itchy skin rash, dry skin, or cracks in the skin.

BALVERSA™ may affect fertility in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all possible side effects of BALVERSA™. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Keep BALVERSA™ out of the reach of children.

 

General information about the safe and effective use of BALVERSA™.
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use BALVERSA™ for a condition for which it was not prescribed. Do not give BALVERSA™ to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information about BALVERSA™ that is written for healthcare professionals.

 

Please click here to see full BALVERSA™ Prescribing Information.

cp-69606v1